Edition:
United Kingdom

Zafgen Inc (ZFGN.OQ)

ZFGN.OQ on NASDAQ Stock Exchange Global Select Market

5.13USD
10 Dec 2018
Change (% chg)

$0.01 (+0.20%)
Prev Close
$5.12
Open
$5.12
Day's High
$5.18
Day's Low
$4.90
Volume
61,475
Avg. Vol
80,057
52-wk High
$12.35
52-wk Low
$3.61

Chart for

About

Zafgen, Inc., is a clinical-stage biopharmaceutical company. The Company uses its proprietary methionine aminopeptidase 2 (MetAP2) biology platform to develop novel therapies for patients affected by complex metabolic diseases. Its product candidate is ZGN-1061 which is a novel fumagillin-class MetAP2 inhibitor that is used to... (more)

Overall

Beta: -1.40
Market Cap(Mil.): $94.27
Shares Outstanding(Mil.): 27.48
Dividend: --
Yield (%): --

Financials

  ZFGN.OQ Industry Sector
P/E (TTM): -- 92.25 33.63
EPS (TTM): -1.88 -- --
ROI: -42.22 0.28 15.02
ROE: -42.56 0.94 16.60

FDA puts Zafgen's diabetes trial on hold

Zafgen Inc said on Monday the U.S. Food and Drug Administration had placed a clinical hold on U.S. trials of its experimental diabetes drug, citing possible heart safety risks.

26 Nov 2018

UPDATE 1-U.S. FDA puts Zafgen's diabetes trial on hold

Nov 26 Zafgen Inc said on Monday the U.S. Food and Drug Administration had placed a clinical hold on U.S. trials of its experimental diabetes drug, citing possible heart safety risks.

26 Nov 2018

U.S. FDA puts Zafgen's diabetes trial on hold

Nov 26 Zafgen Inc said on Monday the U.S. Food and Drug Administration (FDA) had placed a clinical hold on the investigational new drug application for a trial of its experimental diabetes drug.

26 Nov 2018

Earnings vs. Estimates